Dyslipidemia remains a cornerstone of atherosclerotic risk and lipid science continues to drive preventive and therapeutic innovation. The Lipidology session covers mechanistic lipid biology, risk assessment, lifestyle and pharmacologic strategies including statins, PCSK9 inhibitors, bempedoic acid and emerging RNA-based therapies. Presentations will explore LDL-centric and non-LDL pathways, triglyceride targeting, lipoprotein(a) biology and new therapeutic targets identified through genetic and functional studies. The session emphasizes practical approaches to risk stratification that combine lipid panels with genetic and imaging data, management of familial hypercholesterolemia, and optimization of combination therapies for high-risk patients. Panel discussions will cover implementation challenges such as adherence, cost, and health-system approaches for secondary prevention. Clinically focused workshops will provide treatment algorithms, titration strategies and guidance for special populations including pregnancy and chronic kidney disease—integrating lipid science with real-world care pathways and the broader Lipidology Conference agenda.